Abstract
Background Parkinson’s disease (PD) is expected to become more common, particularly with an aging population. Diagnosis and monitoring of the disease typically rely on the laborious examination of physical symptoms by medical experts, which is necessarily limited and may not detect the prodromal stages of the disease.
New Method We propose a lightweight (∼20K parameters) deep learning model, to discriminate between resting-state EEG recorded from people with PD and healthy controls. The proposed CRNN model consists of convolutional neural networks (CNN) and a recurrent neural network (RNN) with gated recurrent units (GRUs). The 1D CNN layers are designed to extract spatiotemporal features across EEG channels, which are subsequently supplied to the GRUs to discover temporal features pertinent to the classification.
Results The CRNN model achieved 99.2% accuracy, 98.9% precision, and 99.4% recall in classifying PD from healthy controls (HC). Interrogating the model, we further demonstrate that the model is sensitive to dopaminergic medication effects and predominantly uses phase information of the EEG signals.
Comparison with Existing Methods The CRNN model achieves superior performance compared to baseline machine learning methods and other recently proposed deep learning models.
Conclusion The approach proposed in this study adequately extracts the spatial and temporal features in multi-channel EEG signals that enable the accurate differentiation between PD and HC. It has excellent potential for use as an oscillatory biomarker for assisting in the diagnosis and monitoring of people with PD. Future studies to further improve and validate the model’s performance in clinical practice are warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by Rina M. Bidin Foundation Fellowship in Research of Brain Treatment (SL), NSERC Canada (MJM), and John Nichol Chair in Parkinsons Research (MJM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Clinical Research Ethics Board at the University of British Columbia (UBC)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, SL, upon reasonable request.
